RADIOPHARMACEUTICALS & THERANOSTICS
The novel field of Radiopharmaceuticals and Theranostics is revolutionizing the way we diagnose and treat cancers with higher certainty and effectiveness. The UCC Research Team is leading the way and is one of only a select handful of major cancer centers leading the way in the U.S. today. Patients travel to UCC from coast to coast for this therapeutic option. Until recently these same patients, if they had the ability, would attempt to get into a center in Munich, Germany for such a treatment.
WHAT IS A RADIOPHARMACEUTICAL?
Radiopharmaceuticals are used to find even the smallest amounts of cancer in the body and accurately treat each identified area of cancer. Radiopharmaceuticals are a very small radioisotope that act like a highly effective guided missile and will travel only to a target that has been identified as unique to a cancer cell. Radiopharmaceuticals can be "Diagnostic" to locate cancer or "Therapeutic" to treat a cancer.
The radiopharmaceutical is typically injected into a vein like an ordinary shot. The radiopharmaceutical agent travels directly and only to specific targets on the cancer cells that it was designed to reach. If the purpose was to find the cancer a Diagnostic radiopharmaceutical agent would be used (example Ga68 PSMA). If the goal is to treat the cancer the diagnostic radioisotope would be replaced with a Therapeutic isotope (Lu177 PSMA, Ac225 PSMA) and then the radiopharmaceutical would travel to the same cancer cells to destroy.
WHAT IS THERANOSTICS?
Theranostics is a term commonly used in this developing field. It is a combination of "Thera" from Therapeutic and "nostics" from Diagnostics. Again defining the ability of radiopharmaceuticals to be both diagnostic and therapeutic.
WHAT ARE THE SIDE EFFECTS?
These are in clinical trials today to expand the knowledge on effectiveness and safety/side effects. We expect no side effects with "Diagnostic" radioisotopes and considered them to be very safe. For the most part to date, the "Therapeutic" radioisotopes appear to be very well tolerated with minimal to manageable side effects. This depends on the radioisotope used (Lu177, Ac225, Th227), the dose used, the type of cancer, the extent of cancer, and more.
UCC IS AT THE CENTER OF THIS ADVANCEMENT
Prostate cancer is leading the charge when it comes to radiopharmaceutical development and UCC is at the head of that charge. Lu177 PSMA was the first agent focused on for prostate cancer. Until recently it was only available for a very high dollar amount in Germany and Australia. Reports flooding the internet and social media about men looking at hospice having complete responses to radiopharmaceuticals with minimal side effects.
A large Global clinical trial with Lu177PSMA was studied. 800 men worldwide were enrolled. UCC enrolled the first patient in the world and enrolled more than 50 of the 800 patients. Patients traveled to UCC from coast to coast for this treatment. Newer agents that have equal excitement around them,Ac225 and Th227, are now entering clinical trials for the first time in the U.S. Three centers have been chosen to perform these clinical trials: Memorial Sloan Kettering (NYC), Tulane (New Orleans), and The Urology Cancer Center (Omaha).
The future of Radiopharmaceuticals is extremely exciting and promising.
Call Today for an Expert 2nd Opinion and see if you qualify for this new treatment technology
Your UCC Cancer Team brings all of the FDA approved standard of care treatments to the fight against your cancer. However, more than ANY other cancer center in the U.S., the UCC Cancer Team has the most access to the latest cutting edge clinical research trials providing potentially life-saving treatments. Cancer research is the only way to discover and utilize new treatments for cancer patients. The Urology Center's Research Team is Globally recognized as a leader by scientific thought leaders, patients and pharmaceutical companies Contact us today for the expert 2nd opinion that you deserve to see how we can bring the best fight against your cancer!Start Your Care